PriceTargets.com logo

Theseus Pharmaceuticals - THRX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $6.75
  • Forecasted Upside: 66.26%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$4.06 As of 02/14/2024 01:00 AM ET
+0 (0.00%)
Get New Theseus Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for THRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for THRX

Analyst Price Target is $6.75
▲ +66.26% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Theseus Pharmaceuticals in the last 3 months. The average price target is $6.75, with a high forecast of $9.00 and a low forecast of $4.00. The average price target represents a 66.26% upside from the last price of $4.06.

This chart shows the closing price for THRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 4 polled investment analysts is to moderate buy stock in Theseus Pharmaceuticals. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/10/2023WedbushReiterated RatingOutperform$7.00Low
7/14/2023Cantor FitzgeraldLower TargetOverweight$23.00 ➝ $7.00N/A
7/14/2023Stifel NicolausLower Target$24.00 ➝ $4.00N/A
7/14/2023WedbushLower TargetOutperform$24.00 ➝ $7.00N/A
7/14/2023Needham & Company LLCDowngradeBuy ➝ HoldN/A
7/14/2023HC WainwrightLower TargetBuy$22.00 ➝ $9.00N/A
3/15/2023Stifel NicolausInitiated CoverageBuy$24.00Low
3/10/2023Needham & Company LLCReiterated RatingBuy$23.00Low
3/10/2023HC WainwrightReiterated RatingBuy$22.00Low
12/14/2022Needham & Company LLCInitiated CoverageBuy$22.00Low
6/30/2022HC WainwrightInitiated CoverageBuy$22.00Low
4/1/2022Cantor FitzgeraldReiterated RatingOverweightN/A
11/1/2021SVB LeerinkInitiated CoverageOutperform$28.00High
11/1/2021WedbushInitiated CoverageOutperform$24.00High
11/1/2021Jefferies Financial GroupInitiated CoverageBuy$23.00Medium
11/1/2021Cantor FitzgeraldInitiated CoverageOverweight$25.00Medium
(Data available from 4/26/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Theseus Pharmaceuticals logo
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. As of February 14, 2024, Theseus Pharmaceuticals, Inc. operates as a subsidiary of Concentra Biosciences, LLC.
Read More

Today's Range

Now: $4.06
Low: $4.06
High: $4.06

50 Day Range

MA: $4.06
Low: $4.06
High: $4.07

52 Week Range

Now: $4.06
Low: $2.05
High: $12.37

Volume

N/A

Average Volume

592,167 shs

Market Capitalization

$179.57 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.98

Frequently Asked Questions

What sell-side analysts currently cover shares of Theseus Pharmaceuticals?

The following Wall Street sell-side analysts have issued stock ratings on Theseus Pharmaceuticals in the last twelve months: Cantor Fitzgerald, HC Wainwright, Needham & Company LLC, Stifel Nicolaus, and Wedbush.
View the latest analyst ratings for THRX.

What is the current price target for Theseus Pharmaceuticals?

4 Wall Street analysts have set twelve-month price targets for Theseus Pharmaceuticals in the last year. Their average twelve-month price target is $6.75, suggesting a possible upside of 66.3%. HC Wainwright has the highest price target set, predicting THRX will reach $9.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $4.00 for Theseus Pharmaceuticals in the next year.
View the latest price targets for THRX.

What is the current consensus analyst rating for Theseus Pharmaceuticals?

Theseus Pharmaceuticals currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for THRX.

What other companies compete with Theseus Pharmaceuticals?

Other companies that are similar to Theseus Pharmaceuticals include NGM Biopharmaceuticals, Kinnate Biopharma, Omeros, 908 Devices and Kodiak Sciences. Learn More about companies similar to Theseus Pharmaceuticals.

How do I contact Theseus Pharmaceuticals' investor relations team?

The company's listed phone number is 857-400-9491 and its investor relations email address is [email protected]. The official website for Theseus Pharmaceuticals is theseusrx.com. Learn More about contacing Theseus Pharmaceuticals investor relations.